A natural fiber complex reduces body weight in the overweight and obese: a double-blind, randomized, placebo-controlled study.

作者: Barbara Grube , Pee‐Win Chong , Kai‐Zhia Lau , Hans‐Dieter Orzechowski

DOI: 10.1002/OBY.20244

关键词: Weight lossGastroenterologyMedicineOverweightEndocrinologyObesityInternal medicinePopulationPlacebo-controlled studyPlaceboIntention-to-treat analysisBody mass index

摘要: Objective: A proprietary natural fiber complex (Litramine IQP G-002AS) derived from Opuntia ficus-indica, and standardized on lipophilic activity, was previously shown in preclinical human studies to reduce dietary fat absorption through gastrointestinal (GI) binding. Here, we investigated the efficacy safety of G-002AS body weight reduction. Design Methods: One hundred twenty-five overweight obese adults participated study. Subjects were advised physical received nutritional counseling, including hypocaloric diet plans (30% energy 500 kcal deficit/day). After a 2-week placebo run-in phase, subjects randomized receive either 3 g/day (IQ) or placebo. The primary endpoint change baseline; secondary endpoints included additional obesity measures parameters. Results: One twenty-three completed 12-week treatment phase (intention-to-treat (ITT) population: 30 male 93 female; mean BMI: 29.6 ± 2.8 kg/m2 age: 45.4 11.3 years). baseline 3.8 1.8 kg IQ vs. 1.4 2.6 (P < 0.001). More lost at least 5% their initial compared = 0.027). Compared with placebo, also showed significantly greater reduction BMI, composition, waist circumference. well tolerated no adverse reactions reported. Conclusions: These results suggest that Litramine is effective promoting loss.

参考文章(24)
L Sjöström, M L Drent, I Larsson, T William-Olsson, W Strobel, F Czubayko, F Quaade, E A van der Veen, K von Bergmann, Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. International Journal of Obesity. ,vol. 19, pp. 221- 226 ,(1995)
A Romero-Corral, V K Somers, J Sierra-Johnson, R J Thomas, M L Collazo-Clavell, J Korinek, T G Allison, J A Batsis, F H Sert-Kuniyoshi, F Lopez-Jimenez, Accuracy of body mass index in diagnosing obesity in the adult general population. International Journal of Obesity. ,vol. 32, pp. 959- 966 ,(2008) , 10.1038/IJO.2008.11
M L Drent, E A van der Veen, Lipase inhibition: a novel concept in the treatment of obesity International Journal of Obesity. ,vol. 17, pp. 241- 244 ,(1993)
Gretchen Stevens, Maya Mascarenhas, Colin Mathers, Global health risks: progress and challenges. Bulletin of The World Health Organization. ,vol. 87, pp. 646- 646 ,(2009) , 10.2471/BLT.09.070565
Stephan Rössner, Lars Sjöström, Rudolf Noack, A. Edo Meinders, Giorgio Noseda, , Weight Loss, Weight Maintenance, and Improved Cardiovascular Risk Factors after 2 Years Treatment with Orlistat for Obesity Obesity Research. ,vol. 8, pp. 49- 61 ,(2000) , 10.1038/OBY.2000.8
Thomas A Wadden, Albert J Stunkard, Social and Psychological Consequences of Obesity Annals of Internal Medicine. ,vol. 103, pp. 1062- 1067 ,(1985) , 10.7326/0003-4819-103-6-1062
K. Johansson, K. Neovius, S. M. DeSantis, S. Rössner, M. Neovius, Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obesity Reviews. ,vol. 10, pp. 564- 575 ,(2009) , 10.1111/J.1467-789X.2009.00581.X
J. Hauptman, Orlistat in the Long-term Treatment of Obesity in Primary Care Settings Archives of Family Medicine. ,vol. 9, pp. 160- 167 ,(2000) , 10.1001/ARCHFAMI.9.2.160
Nancy S Wellman, Barbara Friedberg, Causes and consequences of adult obesity: health, social and economic impacts in the United States Asia Pacific Journal of Clinical Nutrition. ,vol. 11, pp. S705- S709 ,(2002) , 10.1046/J.1440-6047.11.S8.6.X
L. F. Van Gaal, J. I. Broom, G. Enzi, H. Toplak, Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study European Journal of Clinical Pharmacology. ,vol. 54, pp. 125- 132 ,(1998) , 10.1007/S002280050433